This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content PubMed PubMed Citation

(Hypertension. 2000;35:524.)
© 2000 American Heart Association, Inc.

Awards

Hoechst Marion Roussel Hypertension Research Clinical Fellowship Award 1999

	Introduction

 
The purpose of this program and research award is to stimulate physicians-in-training to pursue a career in clinical research in hypertension. The research fellow must be conducting work in which he is the major senior investigator in any area of his choice, including clinical or laboratory aspects of the hypertensive diseases. The fellow’s work would be supervised by the director of the research training program (the mentor), but the conduct of the investigation is primarily by the research fellow. The winning presentation receives $3000 and the fellow’s mentor receives $25 000 to support the clinical investigative training of a research fellow the following year.

View larger version (118K): [in this window] [in a new window]   Figure 1. David S. Geller, MD, PhD

Dr David Geller received his MD and PhD degrees from New York University School of Medicine. He performed his graduate work in the laboratory of Dr G. Nigel Godson, studying mechanisms of transcriptional regulation in Escherichia coli. He completed his internship and residency in Internal Medicine at Yale New Haven Hospital in 1996 and then undertook a fellowship in Nephrology at Yale University. During his fellowship, he has worked in the laboratory of Dr Richard Lifton, with an interest in understanding genetic factors which underlie hypertension. With Dr Lifton, Dr Geller has identified a novel mendelian form of human hypertension caused by an activating mutation in the mineralocorticoid receptor. The mutation allows for activation of the receptor by novel steroids ligands, thus leading to sodium retention and severe early-onset hypertension in patients carrying this mutation. The findings add to our . . . [Full Text of this Article]